With a market capitalization (market cap) of $1.03B — a measure of how much the company is worth — Beta Bionics, Inc. ranks #2,527 among the 2,549 companies tracked, and 364th in Healthcare as of September 22, 2026. Shares trade at $22.81, up 3.49% on the day.
of 2,549 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series — they can diverge when the share count changes. Those returns are not a CAGR until you pick a start value, an ending value, and years. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation September 22, 2026. Ranking headline cap is the snapshot figure as of September 22, 2026.
| Year | As of | Market cap | Annual change | Year-end close |
|---|---|---|---|---|
| 2026 | Sep 22, 2026 | $1.02B | -24.96% | $22.81 |
| 2025 | Dec 31, 2025 | $1.35B | — | $30.47 |
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Ranking figure $1.03B as of September 22, 2026.
Beta Bionics, Inc.'s ranking market cap is the provider-reported capitalization on the same snapshot as the rest of this site, with a share price of $22.81 as of September 22, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $1.02B on September 22, 2026. See how the ranking works.
Live shares outstanding are not on the quote used for price, so this page does not invent a current share count. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 40,529,051 shares. That figure is an average for the year, not the live count in the market-cap formula.
Multiplying the latest price by those FY 2025 weighted-average shares would give about $924.47M. The ranking uses the provider's reported market cap instead, which reflects a current share count rather than that annual average.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Not in this snapshot
FY 2025 net worth
Largest U.S.-listed names in the same FMP sector — not a hand-picked competitor set.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #13 | Eli Lilly and Company LLY | $1.1T | +0.48% |
| #21 | Johnson & Johnson JNJ | $648.72B | -0.10% |
| #24 |
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of September 22, 2026, Beta Bionics, Inc. (BBNX) is worth $1.03B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, Beta Bionics, Inc.’s book equity is about $287.61M. Market cap is the market value of the outstanding shares. As of September 22, 2026, its market cap is $1.03B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
Beta Bionics, Inc. ranks #2,527 among the 2,549 companies tracked on MarketCapLens. In Healthcare it ranks #364 of 368.
Fundamentals are annual. Figures labeled with their fiscal year. Live ratios use the current price against those annual earnings.
Too little price history
Not in this snapshot
FY 2025
| $468.77B |
| +0.32% |
| #34 | Merck & Co., Inc. MRK | $372.73B | +0.95% |
| #40 | UnitedHealth Group Incorporated UNH | $338.69B | -1.22% |
| #51 | Novartis AG NVS | $268.53B | +0.21% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #2524 | Upwork Inc. UPWK | $1.03B | -0.12% |
| #2525 | Trupanion, Inc. TRUP | $1.03B | -5.48% |
| #2526 | STAAR Surgical Company STAA | $1.03B | +1.62% |
| #2528 | CRA International, Inc. CRAI | $1.03B | -1.99% |
| #2529 | Resolute Holdings Management, Inc. RHLD | $1.02B | +4.76% |
| #2530 | Qfin Holdings, Inc. QFIN | $1.02B | -0.76% |
Beta Bionics, Inc.’s ranking market cap of $1.03B comes from the same snapshot as the rest of this site, as of September 22, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 40,529,051. The historical market-cap series last observed $1.02B on September 22, 2026.
Over the past year, Beta Bionics, Inc.’s market cap is up 1.69%, using historical market-cap records rather than today’s share count applied to past prices.
Beta Bionics, Inc. (BBNX) shares trade at $22.81, up 3.49% on the day, as of September 22, 2026.
Live P/E is share price divided by annual earnings per share. It is blank when earnings are missing, zero, or negative — not a 0× multiple.